Innovative Pharmaceutical Biotech Full Year 2025 Earnings: HK$0.20 loss per share (vs HK$0.068 profit in FY 2024)

Innovative Pharmaceutical Biotech (HKG:399) Full Year 2025 Results

Key Financial Results

• Net loss: HK$345.9m (down by 435% from HK$103.4m profit in FY 2024).
• HK$0.20 loss per share (down from HK$0.068 profit in FY 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Innovative Pharmaceutical Biotech shares are down 15% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Innovative Pharmaceutical Biotech (at least 2 which are a bit concerning), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.